24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
y
medac’s complete range of products
Here you can find an overview of all products offered by medac, listed alphabetically from A to
Z. Please click on the respective medicinal product for more information.
Use the quick search to look for a specific product.
Ingredients (all)
j
Searchterm
5-FU medac
https://international.medac.de/products/products////1/
1/14
24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
5-fluorouracil
Packaging
E
Information
o
Mechanism of action
5-fluorouracil in itself is a non-antineoplastic synthetic fluorinated pyrimidine derivate.
After metabolism, cell division is inhibited by the active metabolites 5-fluorouridine
triphosphate (FUTP) and 5-fluorodeoxyuridine monophosphate (FdUMP).
Known mechanism of action
Blockade of DNA synthesis (inhibition of thymidylate synthase by FdUMP)
Inhibition of RNA synthesis (faulty structuring of RNA by incorporation of FUTP)
DNA strand breaks following incorporation of 5‑fluorodeoxyuridine triphosphate
(phosphorylated FdUMP) in DNA
The inhibitory effects are particularly evident in cells that grow rapidly and thus absorb
5‑fluorouracil to a greater extent.
https://international.medac.de/products/products////1/
2/14
24/12/2021, 09:34
Products - medac GmbH
Adrimedac® 2 mg/ml solution for infusion
Suchbegriff...
c
Mg
y
Ingredient
Doxorubicin hydrochloride
Packaging
E
Information
o
Mechanism of action
Adrimedac® 2 mg/ml solution for infusion has a cytotoxic effect, inhibiting DNA and RNA
synthesis through several mechanisms: intercalation between DNA bases, inhibition of
various enzymes such as topoisomerase II, helicase and DNA and RNA polymerases and
formation of free oxygen radicals.
BCG-medac
https://international.medac.de/products/products////1/
3/14
24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
BCG (Bacillus Calmette Guerin, seed RIVM)
Packaging
E
Downloads
E
Information
o
Mechanism of action
Immunostimulant
Educational Material
f
Bendamustin medac
https://international.medac.de/products/products////1/
4/14
24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
Bendamustine hydrochloride
Packaging
E
Information
o
Mechanism of action
Bendamustin medac is an alkylating substance containing the active substance
bendamustine hydrochloride. The alkalising effect of bendamustine hydrochloride is
essentially based on the cross-linking of DNA single and double strands, which impairs the
synthesis and repair of DNA.
Particularities:
Bendamustine induces more rapid and frequent DNA double strand breaks compared to
melphalan and cyclophosphamide.
Moreover, the repair of bendamustine-induced DNA strand breaks has been shown to be
more difficult and slower compared to cyclophosphamide and carmustine.
Another advantage is that bendamustine does not show any cross-resistance with other
alkylating agents.
https://international.medac.de/products/products////1/
5/14
24/12/2021, 09:34
Bleomedac®
Suchbegriff...
c
Products - medac GmbH
Mg
y
Ingredient
Bleomycin sulphate x
Packaging
E
Information
o
Mechanism of action
Bleomycin has a cytostatic effect because of its specific binding to DNA, where it causes
strand breaks.
After administration, bleomycin forms an active complex with copper (Cu2+) and thus
passes through the cell membrane into the cell interior. When the copper splits off in the
cell plasma, bleomycin binds to DNA in the nucleus. Activated by free oxygen radicals, it
induces strand breaks in the DNA. The greatest susceptibility is shown in cells in the G2
and M phases of the cell cycle.
Capecitabin medac film coated tablets
https://international.medac.de/products/products////1/
6/14
24/12/2021, 09:34
Capecitabin medac film-coated tablets
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
Capecitabine
Packaging
E
Information
o
Mechanism of action
Capecitabine is an orally administered precursor (prodrug) of 5‑fluorouracil (5-FU) and is
activated in a three-step process in the liver and tumour tissue.
1. After rapid absorption in the gastrointestinal tract, capecitabine in the liver is first
metabolised by hepatic carboxylesterase to 5’-deoxy-5-fluorocytidine (5’-DFCR).
2. 5’-DFCR is then converted to 5’-deoxy-5-fluorouridine (5’-DFUR) by cytidine deaminase,
principally located in the liver and tumour tissues.
3. The final catalytic activation occurs by thymidine phosphorylase, which is expressed in
the tumour tissue in greater quantity. This transforms the 5’-DFUR into 5‑FU, resulting in
cytostatic action affecting the tumour tissue in particular.
https://international.medac.de/products/products////1/
7/14
24/12/2021, 09:34
Products - medac GmbH
Carbomedac®
Mg
Suchbegriff...
c
y
Ingredient
Carboplatin x
Packaging
E
Information
o
Mechanism of action
Carboplatin has biochemical properties similar to those of cisplatin, thus producing
predominantly interstrand and intrastrand DNA crosslinks. Carboplatin exhibited
comparable activity to cisplatin against a wide range of tumours regardless of implant site.
Alkaline elution techniques and DNA binding studies have demonstrated the qualitatively
similar modes of action of carboplatin and cisplatin. Like cisplatin, carboplatin induces
changes in the superhelical structure of the DNA, consistent with a ‘DNA-shortening
effect’.
Carmustin Obvius
https://international.medac.de/products/products////1/
8/14
24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
carmustine
Packaging
o
Carmustine Obvius 100 mg powder and solvent for concentrate for solution for infusion

1 vial of powder for concentrate for solution for infusion contains 100 mg carmustine
PZN: 15613843
Cecenu®
https://international.medac.de/products/products////1/
9/14
24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
Lomustine x
Packaging
E
Information
o
Mechanism of action
After oral administration, lomustine breaks down spontaneously, first into a chlorethyl
diazonium ion and then into a chlorethyl carbonium ion. Its cytostatic effect is the result of
the alkylation of the O6 of guanine by the chlorethyl carbonium ion. Bifunctional alkylation
leads to DNA crosslinking and induces apoptosis.
CHEMOSAT®
https://international.medac.de/products/products////1/
10/14
24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
y
Packaging
E
Downloads
E
Information
o
The Hepatic CHEMOSAT® Delivery System is a platform for the administration of
chemosaturation therapy to the liver. The CHEMOSAT® system makes it possible to
administer a chemotherapeutic agent (melphalan hydrochloride) to the liver, allowing for
concentrated doses to be delivered while limiting systemic toxicity. CHEMOSAT® uses a
procedure known as percutaneous hepatic perfusion (PHP). The system uses catheters
placed to isolate the liver’s blood flow from the rest of the body and proprietary filters to
reduce the concentration of the chemotherapeutic agent after it leaves the target organ.
The blood which leaves the liver will be passed out of the body to filters which cover most
of the removed chemotherapy drug before returning back to the body. Since the liver is
isolated from the rest of the body, the chemotherapy drug could be given in higher
concentration than it is possible with systemic chemotherapy. Treatment is carried out by
administering the drug to the entire liver from both visible tumors and possibly undetected
microtumors. A CHEMOSAT® procedure is minimally invasive and can be repeated. The
CHEMOSAT® procedure is carried out in a trained hospital and it usually takes 3-5 hours.
Most patients have to stay after that surgery for a few more days for observation in the
hospital.
https://international.medac.de/products/products////1/
11/14
24/12/2021, 09:34
Products - medac GmbH
e
Suchbegriff...
Your Contact
1
2
3
4
5
f
Mg
y
medac GmbH
Head Office
Theaterstraße 6
22880 Wedel
Germany
u
+(49)4103-8006-0

+(49)4103-8006-100
B
contact@medac.de
Information - Coronavirus
https://international.medac.de/products/products////1/
f
12/14
24/12/2021, 09:34
Products - medac GmbH
Mg
y
Suchbegriff...
General Contact
medac GmbH
Theaterstr. 6
22880 Wedel
u
+49 (0)4103 - 8006-0
B
contact@medac.de
Imprint
Privacy policy
General Terms and Conditions of Sale and Delivery
Contact
Download-Centre
Reporting of side-effects
Last updated on: 03/20/2020.
Copyright © 2021 medac GmbH.
https://international.medac.de/products/products////1/
13/14
24/12/2021, 09:34
Products - medac GmbH
Mg
Suchbegriff...
https://international.medac.de/products/products////1/
y
14/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
y
medac’s complete range of products
Here you can find an overview of all products offered by medac, listed alphabetically from A to
Z. Please click on the respective medicinal product for more information.
Use the quick search to look for a specific product.
Ingredients (all)
j
Searchterm
M
Detimedac®
n
https://international.medac.de/products/products////2/
1/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Dacarbazine
Packaging
E
Information
o
Mechanism of action
Enzymatic conversion into the active metabolites. Further metabolisation occurs
spontaneously. Alkylation of the DNA and RNA as a result of the created methyl carbonium
ion.
M
Epimedac®
n
https://international.medac.de/products/products////2/
2/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Epirubicin hydrochloride
Packaging
E
Information
o
Mechanism of action
Epimedac® exerts its cytostatic effect by inhibiting DNA and RNA synthesis through
various mechanisms: intercalation between the bases of the DNA, inhibition of
topoisomerase II, helicase and DNA and RNA polymerase, and formation of free oxygen
radicals.
M
Etomedac®
n
https://international.medac.de/products/products////2/
3/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Etoposide
Packaging
E
Information
o
Mechanism of action
Etoposide is a semisynthetic derivative of podophyllotoxin used in the treatment of certain
neoplastic diseases. Podophyllotoxins inhibit mitosis by blocking microtubular assembly.
Etoposide inhibits cell cycle progression at a premitotic phase (late S and G2).
It does not interfere with the synthesis of nucleinic acids.
M
Gemedac®
n
https://international.medac.de/products/products////2/
4/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Gemcitabine
Packaging
E
Information
o
Mechanism of action
The active substance gemcitabine is a so-called antimetabolite, a substance resembling a
natural metabolite in chemical terms, but inhibiting metabolic pathway. Gemcitabine is
chemically analogous to the nucleoside cytidine, which is an important building block of
DNA and RNA. The cytostatic effect of gemcitabine is based on the incorporation of
gemcitabine triphosphate (the active form of gemcitabine) into the DNA rather than the
M
body’s own cytidine. As a result, DNA synthesis is inhibited resulting in apoptosis (cell
death).
gliolan®
https://international.medac.de/products/products////2/
n
5/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
5‑aminolevulinic acid hydrochloride
Packaging
E
Information
o
Mechanism of action
5‑aminolevulinic acid, the active substance in gliolan®, is a substance intrinsic to the body
which is absorbed by the body’s cells and metabolised in a series of enzymatic reactions
to fluorescent porphyrins, particularly protoporphyrin IX (PPIX).
M
The malignant glioma tissue (WHO‑grades III‑IV) has also been demonstrated to synthesise
and accumulate porphyrins in response to gliolan® administration. As glioma cells absorb
more of the active substance and transform it more rapidly into PPIX, higher PPIX levels
are found in the cancer cells than in the normal tissue.
After excitation with blue light of a certain wave length (λ = 400‑410 nm), the PPIX in the
tumour shows up in bright red, which can be made visible with the help of a suitably
modified standard neurosurgical microscope (special filter) while the normal brain tissue
appears blue. This way the neurosurgeon can distinguish the tumour more clearly during
brain surgery and remove it with greater precision, avoiding damage to healthy tissue.
n
Gliolan® certification
courses
As a condition of the central European marketing authorisation the European Medicines
Agency (EMA) imposed risk minimisation measures for the use of gliolan®. These are set
out in the product’s ‘Risk Management Plan’, and can be viewed on the EMA website.
https://international.medac.de/products/products////2/
6/14
24/12/2021, 09:36
p
g
Products - medac GmbH
g
The central part of this plan consists of training courses for neurosurgeons wanting to use
Suchbegriff...
gliolan® during resection of malignant gliomas. The training courses are designed to y
minimise the occurrence of serious and undesirable neurological incidents, and bring about
a situation where the product can be used effectively and in compliance with the highest
safety standards.
The courses take place at various qualified centres, and follow a fixed agenda, thereby
covering identical standardised content approved by the EMA. medac has committed to
supply gliolan® only to neurosurgeons who have attended the course and are thus officially
authorised for its use.
If you are interested in attending such a course, please send a message to
gliolan@medac.de or contact us directly at any time should you have any questions.
GRASUSTEK®
c
Ingredient
Pegfilgrastim
Packaging
https://international.medac.de/products/products////2/
n
E
7/14
24/12/2021, 09:36
Products - medac GmbH
Information
g
o
Suchbegriff...
y
Human granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, which regulates
the production and release of neutrophils from the bone marrow. Pegfilgrastim is a covalent
conjugate of recombinant human G-CSF (r-metHuG-CSF) and is produced in Escherichia
coli cells by recombinant DNA technology followed by conjugation with polyethylene glycol
(PEG).
Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance.
Pegfilgrastim causes a marked increase in peripheral blood neutrophil counts within
24 hours, with minor increases in monocytes and/or lymphocytes.
Irinomedac®
c
Ingredient
lrinotecan
n
Packaging
I f
ti
https://international.medac.de/products/products////2/
E
8/14
24/12/2021, 09:36
Products - medac GmbH
Information
o
g
Mechanism of action
Suchbegriff...
y
Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent
which acts as a specific inhibitor of DNA type I topoisomerase. It is metabolised by
carboxylesterase in most tissues to SN-38, which was found to be more active than
irinotecan in purified type I topoisomerase and more cytotoxic than irinotecan against
several murine and human tumour cell lines. The inhibition of DNA type I topoisomerase by
irinotecan or SN-38 induces single-strand DNA lesions which block the DNA replication
fork and are responsible for the cytotoxicity. This cytotoxic activity was found to be timedependent and was specific to the S phase.
In vitro irinotecan and SN-38 were not found to be significantly recognised by the
P‑glycoprotein MDR, and display cytotoxic activities against doxorubicin- and vinblastineresistant cell lines.
Furthermore, irinotecan has a broad antitumour activity in vivo against murine tumour
models (P03 pancreatic ductal adenocarcinoma, MA16/C mammary adenocarcinoma, C38
and C51 colon adenocarcinomas) and against human xenografts (Co-4 colon
adenocarcinoma, Mx-1 mammary adenocarcinoma, ST-15 and SC-16 gastric
adenocarcinomas). Irinotecan is also active against tumours expressing the P-glycoprotein
MDR (vincristine- and doxorubicin-resistant P388 leukaemias).
Besides its antitumour activity, the most relevant pharmacological effect of irinotecan is the
inhibition of acetylcholinesterase.
Leflunomid medac
n
https://international.medac.de/products/products////2/
9/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Leflunomide
Packaging
E
Educational Material
f
medoxa®
n
c
Ingredient
https://international.medac.de/products/products////2/
10/14
24/12/2021, 09:36
Products - medac GmbH
Oxaliplatin
Suchbegriff...
Packaging
g
y
Information
E
o
Mechanism of action
Oxaliplatin is an antineoplastic substance belonging to a new class of platinum-based
compounds in which the platinum atom is complexed with a 1,2‑diaminocyclohexane
(DACH) and an oxalate group.
Oxaliplatin is an enantiomer, cis-[oxalate (trans-l-1,2-DACH) platinum].
Oxaliplatin exhibits a wide spectrum of both in vitro cytotoxicity and in vivo antitumour
activity in a variety of tumour model systems including human colorectal cancer models.
Oxaliplatin also demonstrates in vitro and in vivo activity in various cisplatin resistant
models. A synergistic cytotoxic action has been observed in combination with
5‑fluorouracil both in vitro and in vivo.
Studies on the mechanism of action of oxaliplatin, although not completely elucidated,
show that the aqua-derivatives resulting from the biotransformation of oxaliplatin, interact
with DNA to form both inter and intra-strand cross-links, resulting in the disruption of DNA
synthesis leading to cytotoxic and antitumour effects.
metex® FS (MTX)
n
https://international.medac.de/products/products////2/
11/14
24/12/2021, 09:36
Products - medac GmbH
g
y
Suchbegriff...
c
Ingredient
Methotrexate
Packaging
E
Downloads
E
Videos
E
e
1
2
3
4
5
f
Your Contact
medac GmbH
Head Office
Theaterstraße 6
22880 Wedel
Germany
u
+(49)4103-8006-0

+(49)4103-8006-100
B
contact@medac.de
https://international.medac.de/products/products////2/
n
12/14
24/12/2021, 09:36
Products - medac GmbH
g
Suchbegriff...
y
Information - Coronavirus
f
General Contact
medac GmbH
n
Theaterstr. 6
22880 Wedel
https://international.medac.de/products/products////2/
13/14
24/12/2021, 09:36
u
B
Products - medac GmbH
+49 (0)4103 - 8006-0
g
contact@medac.de
y
Suchbegriff...
Imprint
Privacy policy
General Terms and Conditions of Sale and Delivery
Contact
Download-Centre
Reporting of side-effects
Last updated on: 03/20/2020.
Copyright © 2021 medac GmbH.
n
https://international.medac.de/products/products////2/
14/14
24/12/2021, 09:37
Products - medac GmbH
g
Suchbegriff...
y
medac’s complete range of products
Here you can find an overview of all products offered by medac, listed alphabetically from A to
Z. Please click on the respective medicinal product for more information.
Use the quick search to look for a specific product.
Ingredients (all)
j
Searchterm
metex® PEN (MTX)
M
https://international.medac.de/products/products////3/
1/14
24/12/2021, 09:37
Products - medac GmbH
g
Suchbegriff...
c
Ingredient
Methotrexate
A
Homepage
www.metex-pen.de
y
Packaging
E
Downloads
E
Videos
E
metex® TAB (MTX)
M
https://international.medac.de/products/products////3/
2/14
24/12/2021, 09:37
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Methotrexate
Packaging
E
Educational Material
f
Methotrexat (MTX)
M
c
Ingredient
https://international.medac.de/products/products////3/
3/14
24/12/2021, 09:37
Products - medac GmbH
Methotrexate
Suchbegriff...
Packaging
g
y
E
o
Information
Mechanism of action
Methotrexate is a folic acid antagonist, which competitively inhibits dihydrofolate reductase
and thus prevents the formation of tetrahydrofolic acid. The resulting deficiency of
tetrahydrofolic acid leads to a disruption of thymidine and purine synthesis. In addition, the
inhibition of thymidylate synthase brings about a lack of dTMP and a surplus of dUMP,
likewise resulting in inhibition of DNA synthesis.
mito-extra®
M
c
Ingredient
Mitomycin (40 mg + bladder instillation system)
P k i
https://international.medac.de/products/products////3/
E
4/14
24/12/2021, 09:37
Products - medac GmbH
Packaging
E
Downloads
g
E
Suchbegriff...
Information
y
o
Mechanism of action
Mitomycin inhibits DNA synthesis on a selective basis. For the substance to work most
effectively, a reductive chemical or enzymatic activation is required, giving rise to
semiquinone or hydroquinone. This forms the essential basis for the monofunctional or
bifunctional alkylation of the DNA. The reduction of mitomycin, which is a prerequisite for
the alkylating effect of the substance, has led to the introduction of the term ‘bioreductive
alkylation’. Activated mitomycin is most effective in the late G1 and S phases of the cell
cycle, leading to cross-linking of the DNA strands.
mito-medac®
M
c
Ingredient
Mitomycin (20 mg + bladder instillation system)
Packaging
https://international.medac.de/products/products////3/
E
5/14
24/12/2021, 09:37
Packaging
Products - medac GmbH
E
g
E
Downloads
Suchbegriff...
Information
y
o
Mechanism of action
Mitomycin inhibits DNA synthesis on a selective basis. For the substance to work most
effectively, a reductive chemical or enzymatic activation is required, giving rise to
semiquinone or hydroquinone. This forms the essential basis for the monofunctional or
bifunctional alkylation of the DNA. The reduction of mitomycin, which is a prerequisite for
the alkylating effect of the substance, has led to the introduction of the term ‘bioreductive
alkylation’. Activated mitomycin is most effective in the late G1 and S phases of the cell
cycle, leading to cross-linking of the DNA strands.
Mitomycin medac
M
c
Ingredient
Mitomycin x
https://international.medac.de/products/products////3/
6/14
24/12/2021, 09:37
Products - medac GmbH
E
Packaging
Information
Suchbegriff...
g
y
o
Mechanism of action
The mechanism of action is based for the most part on alkylation of the DNA (and to a
lesser extent of the RNA), with corresponding inhibition of DNA synthesis. The degree of
DNA damage correlates with the clinical effect, and is less marked in resistant cells than in
sensitive ones. As with other alkylating agents, proliferating cells suffer greater damage
than those that are in the rest phase (G0) of the cell cycle. In addition, peroxide-free
radicals are released, especially when a high dose is administered, leading to DNA breaks.
The release of peroxide-free radicals is linked to the organ-specific pattern of side effects.
Navirel®
M
c
Ingredient
Vinorelbine
Packaging
https://international.medac.de/products/products////3/
E
7/14
24/12/2021, 09:37
Products - medac GmbH
o
g
Information
Mechanism of action
Suchbegriff...
y
Vinorelbine is an antineoplastic substance of the vinca alkaloid family.
At the molecular level, vinorelbin affects the tubulin in the microtubular system of the cell.
Vinorelbine inhibits tubulin polymerisation and binds preferentially to mitotic microtubules,
only affecting axonal microtubules at high concentrations. Spiralisation of the tubulin is
induced to a lesser degree than with vincristine. Vinorelbine blocks mitosis in phase G2-M,
causing cell death in interphase or at the following mitosis.
Vinorelbine differs from other vinca alkaloids by a structurally modified catharantine
component.
Oncofolic®
M
c
Ingredient
Disodium folinate
A
Homepage
http://www.oncofolic.de
https://international.medac.de/products/products////3/
8/14
24/12/2021, 09:37
Products - medac GmbH
E
g
Packaging
Information
Suchbegriff...
y
o
Mechanism of action
Folinic acid is the formyl derivative of tetrahydrofolic acid (the active form of folic acid). It is
involved in various metabolic processes, e.g. in purine synthesis, pyrimidine nucleotide
synthesis and amino acid metabolism.
The biochemical rationale for the combination of disodium folinate and fluorouracil is as
follows:
One of the effects of fluorouracil is that it inhibits DNA synthesis by binding thymidylate
synthase. The combination of disodium folinate with fluorouracil results in the formation of
a stable ternary complex consisting of thymidylate synthase,
5‑fluorodeoxy‑uridinemonophosphate and 5,10‑methylenetetrahydrofolate.
This leads to an extended blockade of thymidylate synthase with enhanced inhibition of
DNA biosynthesis, resulting in increased cytotoxicity as compared to fluorouracil
monotherapy.
Ovastat®
M
https://international.medac.de/products/products////3/
9/14
24/12/2021, 09:37
c
Products - medac GmbH
Ingredient
Treosulfan x
Suchbegriff...
g
y
Packaging
E
Information
o
Mechanism of action
Treosulfan is a prodrug of alklylating epoxides.
Under physiological conditions (pH 7.4; 37° C), an enzyme-independent intramolecular
nucleophile substitution takes place. This reaction depends on the humidity and the
temperature. With an epoxide ring closure occurring, methanesulfonic acid splits off one
molecule at a time.
The resulting products 1,2-epoxy-3,4-butanediol-4-methanesulphonate and Ldiepoxybutane bind as active reaction products with biological macromolecules.
The antiproliferative and cytotoxic effect is triggered by DNA alkylation on the N7 guanine
as well as through DNA cross-linking and double strand breaks.
Pamifos®
M
https://international.medac.de/products/products////3/
10/14
24/12/2021, 09:37
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Pamidronic acid, disodium salt
Packaging
E
Information
o
Mechanism of action
Pamidronate generally has a high affinity for calcified tissues. By accumulating on the bone
surface, it inhibits the mineralisation of bone substance, while checking bone
decomposition by inhibiting the osteoclasts. In the course of the decomposition of the
bone substance, the osteoclasts absorb the active substance by phagocytosis. As a
bisphosphonate containing nitrogen, pamidronate inhibits farnesyl pyrophosphate
synthase. The products of this enzyme, farnesyl and geranyl pyrophosphate, are needed to
anchor small G-proteins (including Ras proteins) in the cell membrane. If these G-proteins
are absent, growth factors tied to cell receptors have no further effect on the cell. In
consequence the osteoclasts die off by apoptosis.
M
The principal pharmacological effect is based on the inhibition of bone resorption and
suppression of bone restructuring, which will at least lead to a stabilisation, and as a rule to
an actual increase in the bone mass which relies on physiological hydroxyapatite.
Educational Material
https://international.medac.de/products/products////3/
f
11/14
24/12/2021, 09:37
Products - medac GmbH
e
Your Contact
Suchbegriff...
1
2
3
4
5
f
g
y
medac GmbH
Head Office
Theaterstraße 6
22880 Wedel
Germany
u
+(49)4103-8006-0

+(49)4103-8006-100
B
contact@medac.de
Information - Coronavirus
f
M
https://international.medac.de/products/products////3/
12/14
24/12/2021, 09:37
Products - medac GmbH
g
y
Suchbegriff...
General Contact
medac GmbH
Theaterstr. 6
22880 Wedel
u
+49 (0)4103 - 8006-0
B
contact@medac.de
Imprint
Privacy policy
General Terms and Conditions of Sale and Delivery
Contact
Download-Centre
Reporting of side-effects
M
Last updated on: 03/20/2020.
Copyright © 2021 medac GmbH.
https://international.medac.de/products/products////3/
13/14
24/12/2021, 09:37
Products - medac GmbH
g
Suchbegriff...
https://international.medac.de/products/products////3/
y
14/14
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
y
medac’s complete range of products
Here you can find an overview of all products offered by medac, listed alphabetically from A to
Z. Please click on the respective medicinal product for more information.
Use the quick search to look for a specific product.
Ingredients (all)
M
j
Searchterm
Saliva natura
n
https://international.medac.de/products/products////4/
1/13
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Mucin-based salivary replacement x
Packaging
E
Downloads
E
M
Information
o
Mechanism of action
The saliva substitute Saliva natura contains purely plant-based mucopolysaccharides,
which form a protective, moisturising and nourishing film on the oral mucosa. This provides
long-term moisturising of the mouth and throat. Mucins form a natural barrier on the
mucous membrane against chemical and mechanical influences as well as against germs.
Another ingredient is xylitol which inhibits bacteria causing dental caries such as
Streptococcus mutans. Like sorbitol, xylitol is also known as an effective moisturising
agent.
n
Spectrila®
https://international.medac.de/products/products////4/
2/13
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Asparaginase, recombinant
Packaging
E
Information
o
M
Mechanism of action
ASNase brings about an antineoplastic effect by almost completely depleting the plasma
asparagine concentration. The presence of asparaginic acid and glutamine makes it
possible for healthy cells in the body to synthesise asparagine (ASN) with the help of the
enzyme asparagine synthetase (ASNS). Lymphoblastic tumour cells, however, cannot
themselves produce ASN because of the lack of ASNS; these cells can obtain ASN only
from outlying extracellular areas. ASNase brings about reduced protein, DNA and RNA
synthesis in tumour cells and thus achieves the desired cytotoxic effect, while sparing the
majority of normal cells.
n
Sulfasalazin medac
https://international.medac.de/products/products////4/
3/13
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Sulfasalazine
E
Packaging
M
Surefuser™+
n
https://international.medac.de/products/products////4/
4/13
24/12/2021, 09:38
Products - medac GmbH
E
g
Packaging
Downloads
Suchbegriff...
y
E
o
Information
Medical device
Portable elastomeric pump for the application of continuous infusions
Indications
In cases of serious or chronic disease, continuous infusions are frequently needed – e.g. in
connection with chemotherapy, pain therapy or for the administration of antibiotics.
Surefuser™+ makes it possible for patients to remain at home in familiar surroundings even
during severe phases of their illness.
Functional principle
When the balloon reservoir is filled with a liquid medicinal product, the reservoir (which is
M
made of latex-free isoprene rubber) expands. Once it is full, the reservoir starts to contract
as a result of the pressure that has built up, and so infuses the medicinal product by way of
the infusion tube. The flow control on the infusion tube ensures exact dosing.
Features
A well-established and generally accepted infusion system:
Easy to prepare for the pharmacist
Maintains patient mobility
Low intrinsic weight
Safe
Economical
Product range
The Surefuser™+ system comes with volumes of 50, 100 and 250 ml, allowing for
continuous infusions over a period of 0.5 to 167 hours.
https://international.medac.de/products/products////4/
n
5/13
24/12/2021, 09:38
Products - medac GmbH
g
Syrea®
Suchbegriff...
c
y
Ingredient
Hydroxycarbamid
Packaging
M
E
o
Information
Mechanism of action
Hydroxycarbamide mainly acts by inhibiting the enzyme ribonucleotide reductase. This
enzyme plays a crucial role in the biosynthesis of DNA and is responsible for a continuous
and balanced supply of 4-deoxy-ribonucleotide triphosphates. If these are not present in
sufficient quantity, DNA synthesis and cell division is inhibited.
n
Taxceus®
https://international.medac.de/products/products////4/
6/13
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
y
Packaging
E
Information
o
Mechanism of action
Docetaxel belongs to the pharmacotherapeutic group of taxanes. It is an antineoplastic
agent which acts by promoting the assembly of tubulin into stable microtubules and
inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of
docetaxel to microtubules does not alter the number of protofilaments. Docetaxel disrupts
the microtubular network in cells which is essential for vital mitotic and interphase cellular
functions.
Taxomedac®
n
https://international.medac.de/products/products////4/
7/13
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Paclitaxel
Packaging
E
Information
o
Mechanism of action
Paclitaxel stabilises the microtubules of the mitosis spindles in cells that are dividing. The
molecule binds reversibly to the tubulin units of the microtubulus, prevents
depolymerisation and thus inhibits the dynamic equilibrium of the microtubules between
lengthening and shortening. Through the disruption of microtubule functionality, cell
division is prevented and the cell undergoes apoptosis.
Temomedac®
n
https://international.medac.de/products/products////4/
8/13
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
c
y
Ingredient
Temozolomide
Packaging
E
Information
o
Mechanism of action
Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH
to the active monomethyl triazenoimidazole carboxamide (MTIC).
MTIC spontaneously hydrolyses to form 5-amino-imidazole-4-carboxamide (AIC), a wellknown intermediate product in purine and nucleic acid synthesis, as well as
methylhydrazine, which is thought to be an active alkylating substance.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of
guanine with additional alkylation also occurring at the N7 position. Cytotoxic lesions that
develop subsequently are thought to involve aberrant repair of the methyl adduct.
Hydrolytic decomposition of temozolomide to reactive methylhydrazine (to enlarge, please
click on the picture).
n
https://international.medac.de/products/products////4/
9/13
24/12/2021, 09:38
Products - medac GmbH
g
Suchbegriff...
Topotecan medac
c
y
Ingredient
Topotecan
Packaging
E
Trecondi®
n
https://international.medac.de/products/products////4/
10/13
24/12/2021, 09:38
Products - medac GmbH
g
y
Suchbegriff...
c
Ingredient
Treosulfan x
Packaging
E
Information
o
Mechanism of action
Treosulfan is a prodrug of a bifunctional alkylating agent which has a cytotoxic effect
against haematopoietic precursor cells. The effect of treosulfan is due to its spontaneous
conversion into a mono epoxide intermediate and L-diepoxybutane under physiological
conditions (pH 7.4; temperature 37° C).
The epoxides formed alkylate the nucleophilic centres of deoxyribonucleic acid (DNA) and
are able to induce DNA crosslinks, which are thought to be responsible for the stem cell
degrading and antineoplastic activity.
e
1
2
3
4
5
f
n
Your Contact
medac GmbH
Head Office
https://international.medac.de/products/products////4/
11/13
24/12/2021, 09:38
Products - medac GmbH
Theaterstraße 6
g
22880 Wedel
Germany
Suchbegriff...
u
+(49)4103-8006-0

+(49)4103-8006-100
B
contact@medac.de
Information - Coronavirus
y
f
n
https://international.medac.de/products/products////4/
12/13
24/12/2021, 09:38
Products - medac GmbH
g
y
Suchbegriff...
General Contact
medac GmbH
Theaterstr. 6
22880 Wedel
u
+49 (0)4103 - 8006-0
B
contact@medac.de
Imprint
Privacy policy
General Terms and Conditions of Sale and Delivery
Contact
Download-Centre
Reporting of side-effects
Last updated on: 03/20/2020.
Copyright © 2021 medac GmbH.
n
https://international.medac.de/products/products////4/
13/13
24/12/2021, 09:38
Products - medac GmbH
Mg
Suchbegriff...
y
medac’s complete range of products
Here you can find an overview of all products offered by medac, listed alphabetically from A to
Z. Please click on the respective medicinal product for more information.
Use the quick search to look for a specific product.
Ingredients (all)
j
Searchterm
Trospi® 30mg
https://international.medac.de/products/products////5/
1/8
24/12/2021, 09:38
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
Trospium chloride
Packaging
E
Information
o
Mechanism of action
Spasmolytic effect by reducing the concentration of free calcium ions in the cell.
Anticholinergic effect by inhibiting acetylcholine on the muscarinic receptors of the smooth
muscles.
Urokinase medac
https://international.medac.de/products/products////5/
2/8
24/12/2021, 09:38
Products - medac GmbH
Mg
Suchbegriff...
c
y
Ingredient
Urokinase
Packaging
E
Information
o
Mechanism of action
Urokinase is a naturally occurring enzyme extracted from human urine. It belongs to the
group of peptidases, and occurs in two molecular sizes – a high molecular weight form
(approx.. 54 000 D) and a low molecular weight form (approx. MG 33 000 D).
Urokinase belongs to the group of direct plasminogen activators. The single-chain
plasminogen molecule is a plasma protein which transmutes into two-chain plasmin
through hydrolysis. Catalytically active are a series of substances known as plasminogen
activators, which – besides urokinase – also include t-PA and its molecular variants.
Plasmin, an unspecific serine protease and the only known enzyme with fibrinolytic
properties, leads to the dissolution of fibrin clots and due to its non-specificity also
dissolves other clotting agents, like fibrinogen and Factors V and VIII.
The high molecular weight form of urokinase is superior to the low molecular form
in plasmin affinity and activation potency. Commercial urokinase preparations therefore
preferably contain high-molecular weight urokinase.
Characteristics
Urokinase is a white lyophilisate. The pH value of the reconstituted solution is around
6.5‑7.5. The elimination half-life is approx. 10‑20 minutes.
https://international.medac.de/products/products////5/
3/8
24/12/2021, 09:38
pp
Products - medac GmbH
Elimination
Mg
Inactivation (enzymatic degradation) probably occurs primarily in the liver. The inactive
degradation products are excreted via the bile and primarily via the kidneys.
Suchbegriff...
y
Antigenicity
As a natural occurring protein, urokinase has no antigenic properties. Therefore, a longterm and multi-time administration is possible.
Preparation
The contents of one vial should be dissolved with the following amount of water for
injections:
Urokinase 10 000 medac 2 ml
Urokinase 50 000 medac 2 ml
Urokinase 100 000 medac 2 ml
Urokinase 250 000 medac 5 ml
Urokinase 500 000 medac 10 ml
To avoid foaming, the water should ideally be directed at the vial walls. Do not shake the
vial under any circumstances. The lyophilisate will dissolve completely within 1 or 2
minutes.
Shelf life after preparation of the ready-to-use solution
The reconstituted solution is for immediate use.
The solution prepared under aseptic conditions should not be stored for longer than 8
hours. Microbiological considerations should be taken into account as appropriate.
For drip infusion, the contents of one vial of Urokinase HS medac can be dissolved with
water for injections and further diluted in e.g. 5% or 10% glucose solution or in
physiological saline for a final volume of 50 ml.
The chemical and physical stability of the solution after reconstitution in water for injections
and further dilution with 0.9% sodium chloride solution is 72 hours at room temperature.
After dilution in 5% or 10% glucose solution, the solution should be used immediately.
https://international.medac.de/products/products////5/
4/8
24/12/2021, 09:38
Products - medac GmbH
Mg
Suchbegriff...
Zoledronsäure
medac
c
y
Ingredient
Zoledronic acid
Packaging
E
Information
o
Mechanism of action
Zoledronic acid generally has a high affinity for calcified tissue. By accumulating on the
bone surface it inhibits the mineralisation of bone substance, while checking bone
decomposition by inhibiting the osteoclasts. In the course of the decomposition of the
bone substance, the osteoclasts absorb the active substance by phagocytosis. As a
bisphosphonate containing nitrogen, zoledronic acid inhibits farnesyl pyrophosphate
synthase. The products of this enzyme, farnesyl and geranyl pyrophosphate, are needed to
anchor small G-proteins (including Ras proteins) in the cell membrane. If these G-proteins
are absent, growth factors tied to cell receptors have no further effect on the cell. As a
result the osteoclasts die as part of apoptosis.
The main pharmacological effect is due to inhibition of bone resorption and suppression of
bone restructuring, at least leading to a stabilisation, or as a rule to an actual increase in
the bone mass consisting of physiological hydroxyapatite.
https://international.medac.de/products/products////5/
5/8
24/12/2021, 09:38
Products - medac GmbH
Mg
f
Educational Material
y
Suchbegriff...
e
1
2
3
4
5
f
Your Contact
medac GmbH
Head Office
Theaterstraße 6
22880 Wedel
Germany
u
+(49)4103-8006-0

+(49)4103-8006-100
B
contact@medac.de
Information - Coronavirus
https://international.medac.de/products/products////5/
f
6/8
24/12/2021, 09:38
Products - medac GmbH
Mg
Suchbegriff...
y
General Contact
medac GmbH
Theaterstr. 6
22880 Wedel
u
+49 (0)4103 - 8006-0
B
contact@medac.de
Imprint
Privacy policy
General Terms and Conditions of Sale and Delivery
Contact
Download-Centre
Reporting of side-effects
https://international.medac.de/products/products////5/
7/8
24/12/2021, 09:38
Products - medac GmbH
Mg
Suchbegriff...
https://international.medac.de/products/products////5/
Last updated on: 03/20/2020.
Copyright © 2021 medac GmbH.
y
8/8